MetaCap

Lexicon Pharmaceuticals (LXRX) vs Nuvectis Pharma (NVCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nuvectis Pharma (NVCT) has outperformed Lexicon Pharmaceuticals (LXRX) over the past year, gaining 218.9% versus a gain of 14.2%. Lexicon Pharmaceuticals is the larger company by market cap ($681.2 million vs $666.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LXRX+14.18%NVCT+218.91%
+388%+177%-34%
Nov 21, 20251 yearNov 20, 2026
LXRX-49.67%NVCT+496.62%
+778%+324%-129%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LXRX versus NVCT key metrics
MetricLXRXNVCT
Share price$1.53$19.39
Market cap$681.21M$666.80M
1-day change-8.38%-2.27%
YTD return+33.04%+156.82%
1-year return+14.18%+218.91%
5-year return-67.72%—
EPS (TTM)$-0.15$-2.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$49.80M—
Revenue growth (YoY)+60.24%—
Net income (latest FY)$-50.34M$-26.44M
Gross margin99.45%—
Operating margin-98.21%—
Net margin-101.08%—
52-week high$2.68$29.28
52-week low$1.10$5.77
Distance from 52-week high-42.91%-33.77%
Analyst consensusbuynone
Avg. price target upside+195.42%+82.57%
Average volume2.56M206.37K
Shares outstanding445.23M34.39M
Employees8119
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVCT has outperformed LXRX by 204.7 percentage points over the past year.

About Lexicon Pharmaceuticals

LXRX stock →

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees

About Nuvectis Pharma

NVCT stock →

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

LXRX vs NVCT FAQ

Which is bigger, Lexicon Pharmaceuticals or Nuvectis Pharma?

Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $681.21M compared with $666.80M for Nuvectis Pharma (NVCT).

Which stock has performed better over the past year, LXRX or NVCT?

NVCT returned +218.91% over the past 12 months, compared with +14.18% for LXRX (price return, excluding dividends). Past performance does not predict future results.

Are Lexicon Pharmaceuticals and Nuvectis Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons